文献速递创伤与烧伤重症综合管理与镇静镇痛

肠内谷氨酰胺治疗烧伤的随机试验

A Randomized Trial of Enteral Glutamine for Treatment of Burn Injuries.
PubMed 文献 · N Engl J Med · 2022-09-09
一句话结论严重烧伤患者肠内补充谷氨酰胺未缩短存活出院时间,6个月死亡率与安慰剂组无显著差异。

这项双盲、随机、安慰剂对照试验纳入1209例深二度或三度烧伤患者(平均烧伤面积33%总体表面积),随机接受肠内谷氨酰胺0.5 g/kg/d或安慰剂,主要终点为存活出院时间(90天截尾)。谷氨酰胺组中位存活出院时间40天 vs 安慰剂组38天,竞争风险亚分布风险比0.91(95%CI 0.80-1.04;P=0.17),未达统计学显著。6个月死亡率谷氨酰胺组17.2% vs 安慰剂组16.2%(HR 1.06;95%CI 0.80-1.41),两组严重不良事件无实质差异。结论:严重烧伤患者补充谷氨酰胺未缩短存活出院时间。

要点

  • 严重烧伤(平均烧伤面积33%总体表面积)患者肠内谷氨酰胺0.5 g/kg/d,中位存活出院时间40天 vs 安慰剂组38天,亚分布HR 0.91(95%CI 0.80-1.04;P=0.17),未达统计学显著。
  • 6个月死亡率谷氨酰胺组17.2% vs 安慰剂组16.2%(HR 1.06;95%CI 0.80-1.41)。
  • 两组严重不良事件无实质差异。
  • 谷氨酰胺每4小时经喂养管给药或每日3-4次口服,用至末次植皮术后7天、急性监护病房出院或入院后3个月(以先发生者为准)。
  • 纳入标准:深二度或三度烧伤,烧伤面积≥10%至≥20%总体表面积(取决于年龄),入院72小时内随机。

适用人群与场景

  • 深二度或三度烧伤患者,烧伤面积≥10%至≥20%总体表面积(取决于年龄),入院72小时内纳入。

处置流程与药物剂量

  • 谷氨酰胺0.5 g/kg/d肠内给药,每4小时经喂养管给予或每日3-4次口服,用至末次植皮术后7天、急性监护病房出院或入院后3个月,以先发生者为准。
  • 安慰剂组按相同方案给予安慰剂。

研究设计与关键结果

  • 双盲、随机、安慰剂对照试验,1209例严重烧伤患者随机,1200例纳入分析(谷氨酰胺组596例,安慰剂组604例),平均烧伤面积33%总体表面积。
  • 主要终点:中位存活出院时间谷氨酰胺组40天(四分位距24-87)vs 安慰剂组38天(四分位距22-75),亚分布风险比0.91(95%CI 0.80-1.04;P=0.17)。
  • 6个月死亡率:谷氨酰胺组17.2% vs 安慰剂组16.2%(HR 1.06;95%CI 0.80-1.41)。
  • 两组严重不良事件无实质差异。

证据类型、等级与局限

  • 证据类型:双盲、随机、安慰剂对照试验(RE-ENERGIZE,ClinicalTrials.gov NCT00985205),由美国国防部和加拿大卫生研究院资助。

对床旁实践的改变

  • 作者结论:严重烧伤患者补充谷氨酰胺未缩短存活出院时间。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Glutamine is thought to have beneficial effects on the metabolic and stress response to severe injury. Clinical trials involving patients with burns and other critically ill patients have shown conflicting results regarding the benefits and risks of glutamine supplementation.

METHODS: In a double-blind, randomized, placebo-controlled trial, we assigned patients with deep second- or third-degree burns (affecting ≥10% to ≥20% of total body-surface area, depending on age) within 72 hours after hospital admission to receive 0.5 g per kilogram of body weight per day of enterally delivered glutamine or placebo. Trial agents were given every 4 hours through a feeding tube or three or four times a day by mouth until 7 days after the last skin grafting procedure, discharge from the acute care unit, or 3 months after admission, whichever came first. The primary outcome was the time to discharge alive from the hospital, with data censored at 90 days. We calculated subdistribution hazard ratios for discharge alive, which took into account death as a competing risk.

RESULTS: A total of 1209 patients with severe burns (mean burn size, 33% of total body-surface area) underwent randomization, and 1200 were included in the analysis (596 patients in the glutamine group and 604 in the placebo group). The median time to discharge alive from the hospital was 40 days (interquartile range, 24 to 87) in the glutamine group and 38 days (interquartile range, 22 to 75) in the placebo group (subdistribution hazard ratio for discharge alive, 0.91; 95% confidence interval [CI], 0.80 to 1.04; P = 0.17). Mortality at 6 months was 17.2% in the glutamine group and 16.2% in the placebo group (hazard ratio for death, 1.06; 95% CI, 0.80 to 1.41). No substantial between-group differences in serious adverse events were observed.

CONCLUSIONS: In patients with severe burns, supplemental glutamine did not reduce the time to discharge alive from the hospital. (Funded by the U.S. Department of Defense and the Canadian Institutes of Health Research; RE-ENERGIZE ClinicalTrials.gov number, NCT00985205.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Heyland DK, Wibbenmeyer L, Pollack J, et al. A Randomized Trial of Enteral Glutamine for Treatment of Burn Injuries. N Engl J Med. 2022. PMID: 36082909. doi:10.1056/NEJMoa2203364

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。